Sagimet Biosciences SGMT Q3 2026: AURORA Trial Ignites a Wider Loss
As seen on the 24/7 Wall St. homepage on November 12, 2026.
The wider loss is the cost of going pivotal: R&D jumped to $16.34 million as the first patient was dosed in the AURORA Phase 3 acne trial of denifanstat. Pro forma cash of about $355.8 million funds operations through mid-2029, covering the 2H 2027 topline readout and an NDA.
Continue ReadingShow less
Sagimet Biosciences reported a GAAP loss of $0.31 per share for the third quarter of 2026, missing the Wall Street consensus of $0.26 by roughly 19%, as the company deliberately stepped up spending to launch a pivotal acne study. The quarterly net loss widened to $19.15 million from $12.91 million a year earlier, a direct consequence of a surge in research and development costs.
R&D expense climbed to $16.34 million from $9.73 million in Q3 2025, the primary driver being the initiation of AURORA, Sagimet's registrational Phase 3 trial of denifanstat in moderate to severe acne. The trial dosed its first patient in October 2026 and is designed to enroll roughly 800 patients aged 12 and older, with topline data targeted for the second half of 2027.
CEO David Happel pointed to positive Phase 3 results from Chinese license partner Ascletis as the foundation for moving ahead in the U.S., noting that an NDA for denifanstat was accepted by China's NMPA in December 2025. If the AURORA readout succeeds and an NDA is approved, Happel said denifanstat would be the first oral acne treatment with a novel mechanism of action approved by the FDA in more than 40 years, addressing a market of approximately 10 million Americans with moderate to severe acne.
Sponsored
An October 2026 equity offering provided the financial runway to see the program through. Pro forma cash, cash equivalents, and marketable securities stood at approximately $355.8 million, which management expects to fund operations through mid-2029, covering both the AURORA topline readout and a potential NDA submission.
Beyond denifanstat, Sagimet plans to initiate a Phase 2 trial of follow-on candidate TVB-3567 in acne before the end of 2026, and has scheduled an FDA consultation for the first quarter of 2027 on a Phase 2 combination study pairing denifanstat with resmetirom in MASH. That MASH work is contingent on securing non-dilutive funding, so near-term attention remains squarely on the AURORA enrollment trajectory and the 2H 2027 data readout.
Mentioned: SGMT